Tasimelteon for the Treatment of Non-24-hour Sleep-Wake Disorder (N24HSWD) in Blind Individuals With no Light Perception

NCT01429116 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

200

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-24-Hour Sleep-Wake Disorder

Interventions

DRUG: tasimelteon

Sponsor

Vanda Pharmaceuticals